## DT07 Res'd PCT/PT0 1 5 FEB 2005

PTO-1390 (Rev. 02-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES		ATTORNEY'S DOCKET NUMBER 3213/104						
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
	NTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
	August 2003 (13.08.2003)	16 August 2002 (16.08.2002)						
TITLE OF INVENTION BACTERIAL EFFECTOR PROTEINS WHICH INHIBIT PROGRAMMED CELL DEATH								
APPLICANT(S) FOR DO/EO/US MARTIN, Gregory B.; ABRAMOVITCH, Robert B.; LIN, Nai Wen and KIM, Young-Jin								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1. X This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.								
2. This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.								
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.								
1. $\overline{X}$ The US has been elected (Article 31).								
5. X A copy of the International Application as filed (35 U.S.C. 371(c)(2))								
a. is attached hereto (required only if not communicated by the International Bureau).								
b. has been communicated by the In	b. has been communicated by the International Bureau.							
c. $\overline{\mathrm{X}}$ is not required, as the application was filed in the United States Receiving Office (RO/US).								
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).								
a. is attached hereto.								
b. has been previously submitted ur	b. has been previously submitted under 35 U.S.C. 154(d)(4).							
7. Amendments to the claims of the Internation	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))							
a. are attached hereto (required only if not communicated by the International Bureau).								
b. have been communicated by the International Bureau.								
<u></u>								
$\dot{z}$ d. $\dot{z}$ have not been made and will not	$\stackrel{\leftarrow}{\mathbf{d}}$ d. $\overline{\mathbf{X}}$ have not been made and will not be made.							
8. An English language translation of the ame	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9. An oath or declaration of the inventor(s) (35	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
An English language translation of the anne Article 36 (35 U.S.C. 371(c)(5)).	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).							
Items 11 to 20 below concern document(s) or information included:								
11. An Information Disclosure Statement under	37 CFR 1.97 and 1.98.							
12. An assignment document for recording. As	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
13. A preliminary amendment.	A preliminary amendment.							
14. An Application Data Sheet under 37 CFR 1.	An Application Data Sheet under 37 CFR 1.76.							
15. A substitute specification.								
16. A power of attorney and/or change of addre	ess letter.	, to the						
17. A computer-readable form of the sequence	listing in accordance with PCT Rule 1	3ter.2 and 37 CFR 1.821- 1.825.						
18. A second copy of the published International	A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
19. A second copy of the English language tran	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).							
20. X Other items or information: UNSIGNED	Combined Declaration and	l Power of Attorney						

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the complete form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## DT12 Rec'd PCT/PTO 1 5 FEB 2005

PTO-1390 (Rev. 02-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT-OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICAT	1 0 / 5 2 4 7 5 0 PCT/US03/25247			3213/104				
The following fees have been submitted				CALCULATIONS PTO USE ONLY				
21. X Basic national fee				\$ 300.00	1			
22. X Examination fee  If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)					\$ 200.00			
23. X Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority					100.00			
TOTAL OF 21, 22 and 23 =					\$ 600.00			
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium).  The fee is \$250 for each additional 50 sheets of paper or fraction thereof.								
Total Sheets	Extra Sheets		h addifonal 50 or fraction up to a whole number)	RATE				
157 <sub>- 100 =</sub>	57 <sub>/50 =</sub>		2	x \$250	\$ 500.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(h)).					\$ 130.00			
CLAIMS	NUMB	ER FILED	NUMBER EXTRA	RATE	\$			
Total claims		109 - <sup>20 =</sup>	89	× \$ 50	\$ 4,450.00	_		
Independent clair	ms	1 -3=	0	× \$200	\$ 0.00			
MULTIPLE DEPE	MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360				\$ 0.00			
TOTAL OF ABOVE CALCULATIONS =					\$ 5,680.00	1		
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.					2,840.00			
SUBTOTAL =					\$ 2,840.00			
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					\$ 0.00			
TOTAL NATIONAL FEE =					\$ 2,840.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +					\$ 0.00			
****		•	TOTAL F	EES ENCLOSED =	\$	2,840.00		
					Amount to be refunded:	\$		
					Amount to be charged:	\$		
a. $X$ A check in the amount of \$ 2,840.00 to cover the above fees is enclosed.								
b. Please charge my Deposit Account No in the amount of \$ to cover the above fees.  A duplicate copy of this sheet is enclosed.								
c. X The Cor Account	mmissioner is here	eby authorized to A duplicate co	charge any additonal fees way of this sheet is enclosed.	hich may be required,	or credit any overpayment	to Deposit		
d. Fees are be inclu	e to be charged to	a credit card. <b>W</b> . I. Provide credit o	ARNING: Information on this card information and authorization	form may become pub ation on PTO-2038.	lic. Credit card informati	on should not		
			CFR 1.495 has not been me on to pending status.	t, a petition to revive	(37 CFR 1.137(a) or (b))	must be filed		
SEND ALL CORRESPONDENCE TO:								
Michael L. Goldman								
Nixon Peabody LLP				Laldman				
Clinton Square P. O. Box 31051  Michael L. G					oluman			
Rochester, NY								
	Rochester, NY 14603-1051  United States of America  30,727  REGISTRATION NUMBER							

## EXPRESS MAIL CERTIFICATE

DOCKET NO.: 3213/104

APPLICANT(S): MARTIN, et al.

TITLE: BACTERIAL EFFECTOR PROTEINS WHICH INHIBIT PROGRAMMED CELL

DEATH

Certificate is attached to the UNSIGNED Combined Declaration and Power of Attorney of the above-named application.

"EXPRESS MAIL" NUMBER: EV522794270US

DATE OF DEPOSIT: February 15, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post", Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Mail Stop: PCT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Shawn A. Lockett

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee

## EXPRESS MAIL CERTIFICATE

DOCKET NO.:

3213/104

APPLICANT(S): MARTIN, et al.

TITLE:

BACTERIAL EFFECTOR PROTEINS WHICH INHIBIT PROGRAMMED CELL

DEATH

Certificate is attached to the Transmittal Letter to the U.S. Designated/Elected Office (DO/EO/US) of the above-named application.

"EXPRESS MAIL" NUMBER: EV522794270US

DATE OF DEPOSIT:

February 15, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Mail Stop: PCT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Shawn A. Lockett

(Typed or printed name of person mailing paper or fee)